KR930702328A - (4r-시스)-1,1-디메틸에틸-6-시아노메틸-2,2-디메틸-1,3-디옥산-4-아세테이트의 합성 방법 - Google Patents

(4r-시스)-1,1-디메틸에틸-6-시아노메틸-2,2-디메틸-1,3-디옥산-4-아세테이트의 합성 방법

Info

Publication number
KR930702328A
KR930702328A KR1019930701130A KR930701130A KR930702328A KR 930702328 A KR930702328 A KR 930702328A KR 1019930701130 A KR1019930701130 A KR 1019930701130A KR 930701130 A KR930701130 A KR 930701130A KR 930702328 A KR930702328 A KR 930702328A
Authority
KR
South Korea
Prior art keywords
compound
formula
dimethyl
solvent
dioxane
Prior art date
Application number
KR1019930701130A
Other languages
English (en)
Other versions
KR0166385B1 (en
Inventor
앨런 밀러
유진 버틀러 도날드
Original Assignee
로널드 에이. 다이놀트
워너-램버트 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로널드 에이. 다이놀트, 워너-램버트 캄파니 filed Critical 로널드 에이. 다이놀트
Publication of KR930702328A publication Critical patent/KR930702328A/ko
Application granted granted Critical
Publication of KR0166385B1 publication Critical patent/KR0166385B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

하기 일반식(Ⅴ)의 화합물을 하기 일반식(Ⅵ)의 화합물로 처리하는 것으로 이루어지는 하기 일반식(I)의 제조방법이 제공된다.
식중, L은 할로겐 또는(여기서, Ar은 아릴임)이다.
본 발명의 제2측면은 일반식(Ⅴ)의 신규한 중간체이다.

Description

(4R-시스)-1,1-디메틸에틸-6-시아노메틸-2,2-디메틸-1,3-디옥산-4-아세테이트의 합성 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (29)

  1. 하기 일반식(Ⅶ)의 화합물을 용매 중의 약 0℃ 내지 약 100℃에서 하기 일반식(Ⅵ)의 화합물로 처리하여 하기 일반식(Ⅰ)의 화합물을 얻는 것을 특징으로 하는 일반식(Ⅰ)의 화합물의 제조방법.
  4. 식중, L은 할로겐 또는(여기서, Ar은 아릴임)이고, M은 알칼리 금속, 은 또는 구리(Ⅰ)이다.
  5. 제1항에 있어서, 단계(a)하기 일반식(Ⅳ)의 화하불을 염기 및 용매의 존재하에 하기 일반식(Ⅴ)의 화합물로 처리하여 하기 일반식(Ⅱ)의 화합물을 얻거나, 또는 단계(b)일반식(Ⅱ)의 화합물을 용매 중의 약0℃ 내지 약 용매의 환류 온도에서 알칼리 요오드화물로 처리하여 하기 일반식(Ⅲ)의 화합물을 얻고, 단계(c)일반식(Ⅱ)의 화합물 또는 일반식(Ⅲ)의 화합물을 용매 중이 약0℃ 내지 약 100℃에서 하기 일반식(Ⅵ)의 화합물로 처리하여 하기 일반식(I)의 화합물을 얻는 것을 특징으로 하는 일반식(I)의 화합물의 제조방법.
  12. 식중, Ar은 아릴이고, X는 할로겐이고, M은 알칼리금속, 은 또는 구리(I)이다.
  13. 제2항에 있어서, 상기 단계 9(a)중의 염기가 트리에틸아민, 디이소프필에틸 아민 및 4-디메틸아미노피리딘으로 이루어진 군 중에서 선택되는 방법.
  14. 제3항에 있어서, 염기가 트리에틸아민인 방법.
  15. 제2항에 있어서, 상기 단계(a)중의 용매가 피리딘, 톨루엔 및 염화메틸렌으로 이루어지는 군 중에서 선택되는 방법.
  16. 제5항에 있어서, 용매가 염화메틸렌인 방법.
  17. 제2항에 있어서, 상기 단계(b)중의 용매가 아세톤 및2-부타논으로 이루어지는 군중에서 선택되는 방법.
  18. 제7항에 있어서, 용매가 2-부타논인 방법.
  19. 제2항에 있어서, 상기 단계(b)중의 알칼리 요오드화물이 요오드화나트륨 및 요오드화칼륨으로 이루어지는 군중에서 선택되는 방법.
  20. 제9항에 있어서, 알칼리 요오드화물이 요오드화나트륨인 방법.
  21. 제2항에 있어서, 상기 단계(c)중의 일반식(Ⅵ)의 화합물이 시안화리륨, 시안화나트륨, 시안화칼륨, 시안화은 및 시안화제일구리로 이루어지는 군 중에서 선택되는 방법.
  22. 제11항에 있어서, 일반식(Ⅵ)의 화합물이 시안화나트륨인 방법.
  23. 제2항에 있어서, 상기 단계(c)중의 용매가 에탄올, 디메틸 술폭시드, 디메틸포롬아미드, 디메틸프로필렌우레아, 디메틸에틸렌우레아, 테트라메틸우레아, N-메틸피롤리디논, 테트라히드록푸란, 염화메틸렌, 염화메틸렌-물 및 4급 암모늄염, 롤루엔, 및 롤루엔-물 및 4급 암모늄염으로 이루어지는 군중에서 선택되는 방법.
  24. 제13항에 있어서, 용매가 디메틸 술폭시드인 방법.
  25. 하기 일반식(Ⅶ)의 화합물.
  27. 식중, L은 할로겐 또는(여기서, Ar은 아릴임)이다.
  28. 제4항에있어서, (4R-시스)-1,1-디메틸에틸6-(4-브로모벤젠)술포닐옥스-2,2-디메틸-1,3-디옥산-4-아세테이트,(4R-시스)-1,1-디메틸에틸6-(4-클로로벤젠)술포닐옥스-2,2-디메틸-1,3-디옥산-4-아세테이트,(4R-시스)-1,1-디메틸에틸6-(2,5-디클로로벤젠)술포닐옥스-2,2-디메틸-1,3-디옥산-4-아세테이트, (4R-시스)-1,1-디메틸에틸6-(2-니트로벤젠)술포닐옥스-2,2-디메틸-1,3-디옥산-4-아세테이트,(4R-시스)-1,1-디메틸에틸6-(4-니트로벤젠)술포닐옥스-2,2-디메틸-1,3-디옥산-4-아세테이트,및 (4R-시스)-1,1-디메틸에틸6-요오드메틸-2,2-디메틸-1,3-디옥산-4-아세테이트로 이루어지는 군중에서 선택되는 화합물.
  29. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930701130A 1990-10-17 1993-04-16 Process for the synthesis of (4r-cis)-1,1-dimethylethyl-6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate KR0166385B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US599,521 1990-10-17
US07/599,521 US5103024A (en) 1990-10-17 1990-10-17 Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
PCT/US1991/006697 WO1992006968A1 (en) 1990-10-17 1991-09-11 Process for the synthesis of (4r-cis)-1,1-dimethylethyl-6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate

Publications (2)

Publication Number Publication Date
KR930702328A true KR930702328A (ko) 1993-09-08
KR0166385B1 KR0166385B1 (en) 1999-01-15

Family

ID=24399962

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930701130A KR0166385B1 (en) 1990-10-17 1993-04-16 Process for the synthesis of (4r-cis)-1,1-dimethylethyl-6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate

Country Status (20)

Country Link
US (1) US5103024A (ko)
EP (1) EP0553213B1 (ko)
JP (1) JP3105923B2 (ko)
KR (1) KR0166385B1 (ko)
AT (1) ATE118772T1 (ko)
AU (1) AU646311B2 (ko)
CA (1) CA2092997C (ko)
CZ (5) CZ282922B6 (ko)
DE (1) DE69107622T2 (ko)
DK (1) DK0553213T3 (ko)
ES (1) ES2070519T3 (ko)
FI (1) FI108539B (ko)
HK (1) HK1005026A1 (ko)
HU (2) HU219237B (ko)
IE (1) IE62940B1 (ko)
NO (1) NO301588B1 (ko)
PT (1) PT99244B (ko)
RU (1) RU2067580C1 (ko)
SK (5) SK280940B6 (ko)
WO (1) WO1992006968A1 (ko)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149837A (en) * 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) * 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960312B1 (en) 1995-07-17 2001-10-31 Warner Lambert Co NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
EP1077212B1 (en) * 1998-04-30 2003-08-20 Kaneka Corporation Process for producing 6-cyanomethyl-1,3-dioxane-4-acetic acid derivatives
HU227840B1 (en) * 1999-05-06 2012-05-02 Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag Intermediates of atorvastatin synthesis and process for producing them
IN191236B (ko) 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
US20040063969A1 (en) * 1999-10-18 2004-04-01 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
JP2003517039A (ja) * 1999-12-17 2003-05-20 ワーナー・ランバート・リサーチ・アンド・ディベロップメント・アイルランド・リミテッド 結晶質アトルバスタチンカルシウムの製造方法
ES2252088T3 (es) 1999-12-17 2006-05-16 Pfizer Science And Technology Ireland Limited Procedimiento de produccion a escala industrial de la hemisal de calcio de la atorvastatina trihidrato cristalina.
US7608445B1 (en) 1999-12-29 2009-10-27 Verenium Corporation Nitrilases, nucleic acids encoding them and methods for making and using them
US7300775B2 (en) 1999-12-29 2007-11-27 Verenium Corporation Methods for producing α-substituted carboxylic acids using nitrilases and strecker reagents
US7521216B2 (en) 1999-12-29 2009-04-21 Verenium Corporation Nitrilases and methods for making and using them
US20040014195A1 (en) * 1999-12-29 2004-01-22 Diversa Corporation Nitrilases, nucleic acids encoding them and methods for making and using them
JP3844112B2 (ja) 2000-08-23 2006-11-08 高砂香料工業株式会社 ３，５，６−トリヒドロキシヘキサン酸アンモニウム塩誘導体、及びその製造方法
EP1728785A1 (en) 2001-01-09 2006-12-06 Warner-Lambert Company LLC 7-[(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-heptanoic acid ester 3,5-dioxo-acetal
US6476235B2 (en) 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) * 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
MXPA03010266A (es) 2001-06-29 2004-03-10 Warner Lambert Co Formas cristalinas de la sal de calcio del acido [r-(r*, r*)]-2 -(4-fluorofenil)-¦, d-dihidroxi-5 -(1-metiletil)-3 -fenil-4- [(fenilamino) carbonil ]-1h- pirrol-1-heptanoico (2:1) (atorvastatin).
GB0116212D0 (en) * 2001-07-03 2001-08-29 Avecia Ltd Process
JP2005500351A (ja) 2001-07-30 2005-01-06 ドクター・レディーズ・ラボラトリーズ・リミテッド 結晶形態ｖｉおよびｖｉｉのアトルバスタチンカルシウム
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
AU2001284385A1 (en) * 2001-08-31 2003-03-10 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
HU227124B1 (en) * 2001-09-14 2010-07-28 Egis Gyogyszergyar Nyilvanosan Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs) * 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
DE10212492B4 (de) * 2002-03-21 2012-02-02 Daimler Ag Kolbenpumpe
AU2003251523A1 (en) * 2002-06-13 2003-12-31 Diversa Corporation Processes for making (r)-ethyl 4-cyano-3-hydroxybutyric acid
ES2287549T3 (es) * 2002-08-06 2007-12-16 Warner-Lambert Company Llc Procedimiento para preparar la fenilamida del acido 5-(4-fluorofenil)-1-(2-((2r,4r)-4-hidroxi-6-oxo-tetrahidropiran-2-il)etil)-2-isopropil-4-fenil-1h-pirrol-3-carboxilico.
CA2491051A1 (en) * 2002-09-03 2004-03-18 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
KR100529703B1 (ko) * 2002-09-23 2005-11-17 임광민 키랄 중간체의 제조방법 및 그를 이용한 아토바스타틴의제조방법
HRP20020885B1 (en) * 2002-11-11 2007-05-31 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. SUBSTITUTED 9a-N-{N'-[4-(SULFONYL)PHENYLCARBAMOYL]}DERIVATIVES 9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHROMYCIN A AND 5-O-DESOZAMINYL-9-DEOXO-9-DIHYDRO-9a-AZA-9a-HOMOERITHRONOLIDE A
AU2004228463A1 (en) * 2003-04-14 2004-10-21 Warner-Lambert Company Llc Process for preparing 5-(4-fluorophenyl)-1-[2-((R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
US20040248972A1 (en) * 2003-05-16 2004-12-09 Ambit Biosciences Corporation Compounds and uses thereof
US20050182125A1 (en) * 2003-05-16 2005-08-18 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
WO2004110357A2 (en) * 2003-05-16 2004-12-23 Ambit Biosciences Corporation Heterocyclic compounds and uses thereof
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
EP2522656A3 (en) 2003-07-25 2013-03-20 Redx Pharma Limited Process and Intermediate Compounds Useful in the Preparation of Statins, Particularly Atorvastatin
KR100781420B1 (ko) * 2003-09-17 2007-12-03 워너-램버트 캄파니 엘엘씨 [Ｒ-(Ｒ*,Ｒ*)]-2-(4-플루오로페닐)-β,δ-다이하이드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카보닐]-1Ｈ-피롤-1-헵탄산의 결정성 형태
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
SI1727795T1 (sl) 2004-03-17 2012-05-31 Ranbaxy Lab Ltd Postopek za pripravo atorvastatin kalcija v amorfni obliki
JP2007532622A (ja) * 2004-04-16 2007-11-15 ファイザー・プロダクツ・インク 非晶質アトルバスタチン・カルシウムの形成方法
BRPI0510713A (pt) 2004-05-05 2007-11-20 Pfizer Prod Inc formas de sal de ácido [r-(r*,r*)]-2-(4-fluorofenil)-beta, delta-diidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)ca rbonil]-1h-pirrol-1- heptanóico
EP1771455B1 (en) * 2004-07-16 2016-05-11 LEK Pharmaceuticals d.d. Oxidative degradation products of atorvastatin calcium
WO2006011041A2 (en) 2004-07-20 2006-02-02 Warner-Lambert Company Llc Crystalline forms of (r-(r*))-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-hept anoic acid calcium salt (2:1)
EP1784389A4 (en) * 2004-08-27 2009-03-25 Biocon Ltd PROCESS FOR THE PREPARATION OF AMORPHIC ATORVASTATIN CALCIUM
CN101048141A (zh) 2004-10-28 2007-10-03 沃尼尔·朗伯有限责任公司 形成非晶形的阿托伐他汀的方法
CA2588216A1 (en) 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
JP2009507822A (ja) * 2005-09-09 2009-02-26 ファイザー・サイエンス・アンド・テクノロジー・アイルランド・リミテッド アトルバスタチン中間体の調製
ATE432276T1 (de) * 2005-09-09 2009-06-15 Pfizer Science & Tech Ltd Herstellung eines atorvastatin-zwischenprodukts
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
ES2304335T3 (es) * 2005-11-21 2010-05-19 Warner-Lambert Company Llc Formas nuevas del acido (r-(r*,r*))-2-(4-fluorofenil)-b,b-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)1h-pirrol-1-heptanoico, de magnesio.
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
WO2008053312A2 (en) * 2006-11-02 2008-05-08 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its intermediate
US7834195B2 (en) * 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
WO2008106662A2 (en) 2007-03-01 2008-09-04 Verenium Corporation Nitrilases, nucleic acids encoding them and methods for making and using them
US20110142883A1 (en) * 2007-07-20 2011-06-16 Actavis Group Ptc Ehf Amorphous Coprecipitates of Atorvastatin Pharmaceutically Acceptable Salts
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
US8115015B2 (en) * 2009-01-26 2012-02-14 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
WO2012032035A1 (en) 2010-09-09 2012-03-15 Dsm Sinochem Pharmaceuticals Netherlands B.V. Salts of 7-amino-3,5-dihydroxyheptanoic acid esters
MX2013015272A (es) 2011-07-01 2014-04-14 Dsm Sinochem Pharm Nl Bv Cristales micronizados.
WO2016056031A1 (en) 2014-10-08 2016-04-14 Council Of Scientific & Industrial Research Novel diol compounds synthesis and its use for formal synthesis of (2r, 3 s)-3-hydroxypipecolic acid
CN106008251A (zh) * 2016-05-19 2016-10-12 河南豫辰药业股份有限公司 一种2-苯甲撑-3-氧代-4-甲基-n-苯基戊酰胺的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5093363A (en) * 1989-08-22 1992-03-03 Shionogi & Co., Ltd. 2,4,6-substituted phenol derivatives
DE3929913A1 (de) * 1989-09-08 1991-04-04 Hoechst Ag 4-hydroxytetrahydropyran-2-one sowie die entsprechenden dihydroxycarbonsaeurederivate, salze und ester, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate sowie vorprodukte

Also Published As

Publication number Publication date
SK280938B6 (sk) 2000-09-12
CZ124797A3 (en) 1997-12-17
EP0553213A1 (en) 1993-08-04
NO931421D0 (no) 1993-04-16
SK280941B6 (sk) 2000-09-12
SK280939B6 (sk) 2000-09-12
RU2067580C1 (ru) 1996-10-10
IE62940B1 (en) 1995-03-08
FI931680A0 (fi) 1993-04-14
FI108539B (fi) 2002-02-15
SK280942B6 (sk) 2000-09-12
HUT64049A (en) 1993-11-29
SK280940B6 (sk) 2000-09-12
FI931680A (fi) 1993-04-14
AU8848091A (en) 1992-05-20
CZ282922B6 (cs) 1997-11-12
CZ282994B6 (cs) 1997-12-17
CZ124697A3 (en) 1997-12-17
HU219237B (en) 2001-03-28
IE913629A1 (en) 1992-04-22
CZ209495A3 (en) 1997-12-17
HK1005026A1 (en) 1998-12-18
CA2092997A1 (en) 1992-04-18
EP0553213B1 (en) 1995-02-22
KR0166385B1 (en) 1999-01-15
DK0553213T3 (da) 1995-07-17
DE69107622D1 (de) 1995-03-30
JPH06502162A (ja) 1994-03-10
CZ61493A3 (en) 1994-02-16
US5103024A (en) 1992-04-07
DE69107622T2 (de) 1995-07-06
CZ282993B6 (cs) 1997-12-17
CA2092997C (en) 2002-05-14
SK33993A3 (en) 1993-10-06
HU9301122D0 (en) 1993-08-30
PT99244B (pt) 1999-04-30
PT99244A (pt) 1992-09-30
CZ282992B6 (cs) 1997-12-17
AU646311B2 (en) 1994-02-17
HU9701183D0 (en) 1997-09-29
ES2070519T3 (es) 1995-06-01
JP3105923B2 (ja) 2000-11-06
WO1992006968A1 (en) 1992-04-30
HU213731B (en) 1997-09-29
NO931421L (no) 1993-06-16
NO301588B1 (no) 1997-11-17
CZ283003B6 (cs) 1997-12-17
ATE118772T1 (de) 1995-03-15
CZ124597A3 (en) 1997-12-17

Similar Documents

Publication Publication Date Title
KR930702328A (ko) (4r-시스)-1,1-디메틸에틸-6-시아노메틸-2,2-디메틸-1,3-디옥산-4-아세테이트의 합성 방법
KR870003989A (ko) 치환 및 이치환 피리딘-2,3-디카르복실레이트의 제조방법과 치환된 니코티네이트의 제조방법
KR860001104A (ko) 테트라히드로프탈이미드의 제조방법
KR950032203A (ko) 깅콜라이드 c로부터의 깅콜라이드 b의 제조 방법
KR840005097A (ko) 비닐 카르복실산 유도체의 제조방법
KR840007882A (ko) 디히드로피리딘 유도체 및 그 제법
KR830010069A (ko) 옥신돌 유도체의 제조방법
KR840006233A (ko) 티오펜 유도체의 제조방법
PT91113A (pt) Processo para a producao de o/indice 2,2'-anidro-1-(b-d-arabinofurano-sil)timina
KR840005723A (ko) 티아졸유도체의 제조방법
PT98672A (pt) Processo para a preparacao de corantes
KR880001615A (ko) 5,6-치환-2,4-퀴나졸인디아민 및 신규의 중간 생성물을 제조하는 향상된 방법
KR860004038A (ko) 결정상 벤조티아진 디옥사이드 염의 제조방법
KR840001947A (ko) 페녹시알킬아마이드 유도체의 제조방법
KR860008123A (ko) 신규 디아민 유도체의 제조방법
KR840000524A (ko) β-시클로-치환 에틸아민의 제조방법
KR850006394A (ko) 치환된 옥시란의 제조방법
KR840009105A (ko) 1,4-디하이드로피리딘 유도체의 제조방법
KR900011730A (ko) 이미드 메틸프탈로시아닌 유도체의 제조방법
KR830005255A (ko) N-포스포노메틸글리시노니트릴 디아릴 에스테르의 퍼플루오로아미드의 제조방법
KR900016100A (ko) 카바메이트 유도체 및 이의 제조방법
KR870008838A (ko) 아릴술폰 화합물 제조방법
KR850006422A (ko) 세팔로스포린 유도체의 제조방법
KR970001338A (ko) 크라운 에테르형 시클로판 화합물 및 그의 제조 방법
KR910011829A (ko) 신규 디페닐 유도체

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20080711

Year of fee payment: 11

LAPS Lapse due to unpaid annual fee